Boston Scientific Earnings & Forecasts

Boston Scientific (BSX) earnings history, EPS estimates, revenue forecasts and company guidance.

Earnings Per Share (Non-GAAP)

四半期利益の驚きの金額

会計四半期	報告日	実質EPS	推定EPS	驚き％
Q2	Jul 29, 2026	$0.86	$0.83	3.61 %
Q1	Apr 22, 2026	$0.80	$0.79	1.27 %
Q4	Feb 4, 2026	$0.80	$0.78	2.56 %
Q3	Oct 22, 2025	$0.75	$0.71	5.63 %

Quarterly Revenue (Billions)

四半期売上高の驚きの金額

会計四半期	報告日	実際の収益	推定収益	驚き％
Q2	Jul 29, 2026	$5.44B	$5.38B	1.22 %
Q1	Apr 22, 2026	$5.20B	$5.18B	0.45 %
Q4	Feb 4, 2026	$5.29B	$5.28B	0.18 %
Q3	Oct 22, 2025	$5.07B	$4.97B	1.86 %

Boston Scientific Guidance

Boston Scientific (BSX) は、7 29, 2026 年に Q3 2026 のガイダンスを最後に発表しました。同社は 1 株当たり利益を $0.8 - $0.82 の範囲と予想し、コンセンサス EPS 予想は $0.84 でした。Boston Scientific も、この期間の売上高を $5.22B - $5.32B の範囲と予想しました。

以前のガイダンスと比較して、Boston Scientificは売上高予測を以前の範囲である引き下げから$21.18B - $21.38Bに引き上げました。

Boston Scientificは、35から10 26, 2022の間に7 29, 2026ガイダンスの更新を発表しました。During this period, the company raised its outlook 13 times and lowered it 18 times, providing investors with insight into management's evolving expectations.

Recent Earnings Results

Metric	Q2 '26	Q1 '26	Q4 '25	Q3 '25
Earnings Per Share (Non-GAAP)
Estimate	$0.83	$0.79	$0.78	$0.71
Actual	$0.86	$0.80	$0.80	$0.75
Surprise	+3.61%	+1.27%	+2.56%	+5.63%
Revenue
Estimate	$5.38B	$5.18B	$5.28B	$4.97B
Actual	$5.44B	$5.20B	$5.29B	$5.07B
Surprise	+1.22%	+0.45%	+0.18%	+1.86%

Analyst Estimates — Forward PeriodsSource: Wall Street consensus

Metric	Q3 '26E	Q4 '26E	Q1 '27E	Q2 '27E
Earnings Per Share (Non-GAAP)
Consensus	$0.80	$0.84	$0.82	$0.87
Revenue
Consensus	$5.26B	$5.43B	—	—

More with Benzinga EdgeGet Access

Earnings & Guidance News

Boston Scientific Cuts Forecast on Product Slowdown and Competition

Boston Scientific beat second-quarter estimates but lowered its 2026 sales and earnings outlook as restructuring costs weighed on guidance.

Vandana Singh

PRO
Boston Scientific Sees Q3 Adj EPS $0.80-$0.82 vs $0.83 Est; Sees Sales $5.217B-$5.318B vs $5.358B Est

Boston Scientific (NYSE:BSX) is looking for Q3 Adj EPS of $0.80-$0.82 vs $0.83 analyst estimate. sees sales of $5.217 billion-$5.318 billion vs $5.358 billion analyst estimate.

Benzinga Newsdesk

PRO
Boston Scientific Lowers FY2026 Adj EPS Guidance from $3.34-$3.41 to $3.28-$3.32 vs $3.36 Est; Lowers FY2026 Sales Guidance from $21.479B-$21.780B to $21.178B-$21.379B vs $21.562B Est

Boston Scientific (NYSE:BSX) lowers FY2026 Adj EPS guidance from $3.34-$3.41 to $3.28-$3.32 vs $3.36 analyst estimate. Lowers FY2026 sales outlook from $21.479 billion-$21.780 billion to $21.178 billion-$21.379 billion

Benzinga Newsdesk

Boston Scientific Corp